Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.

The trials by Dr. Toni K. Choueiri showed a confirmed overall response rate of 46% in patients who completed a minimum of 12 weeks of follow-up. The trials conducted through casdaifan also included a HIF-2a inhibitor, cabozantinib, a tyrosine kinase inhibitor. The combination had a manageable safety profile with no meaningful overlapping toxicity for the two drugs.

Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

A scientist researching the innate and adaptive immune response in a biopharmaceutial laboratory.

“These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment,” said Terry Rosen, Ph.D., chief executive officer of Arcus.

Arcus Biosciences, Inc. (NYSE:RCUS) is working on a broad development program with the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations. This program focuses on maximising the opportunity for casdatifan in clear cell renal cell carcinoma (ccRCC) patients.

Arcus Biosciences, Inc. (NYSE:RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer.

While we acknowledge the potential of RCUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.